Doctors inclined to prescribe new Alzheimer’s drug despite concerns

Jared Whitlock

Features Editor

Beth Snyder Bulik

Senior Editor

Doctors who treat Alzheimer’s patients say they’re likely to prescribe Eisai and Biogen’s new therapy approved Friday, but sounded notes of caution over the lack …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Doctors inclined to prescribe new Alzheimer’s drug despite concerns

Jared Whitlock

Features Editor

Beth Snyder Bulik

Senior Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Doc­tors in­clined to pre­scribe new Alzheimer’s drug de­spite con­cerns

Features Editor

Senior Editor

Sign up to read this article for free.

Doctors inclined to prescribe new Alzheimer’s drug despite concerns